>Transplant Trials
Patients and Families
Find a Doctor
Find a Clinical Trial
Transplant Trials
Bone marrow transplant with a non sibling matched donor requires more intensive conditioning with increased treatment related toxicity. The study treatment plan proposes the use of a reduced toxicity myeloablative conditioning regimen to increase the engraftment potential without serious complication.
Seoul National University Hospital, Seoul, Korea
- Hyoung Jin Kang, Ph.D. 82 2 2072 3304, E Mail: kanghj@snu.ac.kr
- Ji won Lee, M.D. 82 2 2072 0177, E Mail: agnesjw@hanmail.net
This is a trial of bone marrow transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor. The study treatment plan uses a new transplant treatment regimen that aims to try to decrease the acute toxicities and complications associated with the standard treatment plans and to improve outcome
Children's Hospital Los Angeles
- Hisham Abdel-Azim, MD. 323-361-8556, E Mail: habdelazim@chla.usc.edu
Determine the safety of a non-ablative conditioning and post-transplantation immunosuppression regimen who undergo HLA-matched related or unrelated bone marrow transplantation to induce mixed hematopoietic chimerism
Fred Hutchinson Cancer Research Center, Seattle, Washington
- Lauri Burroughs, MD, E Mail: lburroug@fhcrc.org
Donor T lymphocytes that have been treated with the Epstein-Barr virus may help the body build an effective immune response to kill cancer cells. This trial studies the side effects and the best way to give T Lymphocytes in treating patients undergoing a bone marrow transplant.
Baylor College of Medicine, Texas Children's Cancer Center and Methodist Hospital, Houston, TX
- Clinical Trials Office 713-798-1297 or Catherine Perera 832-824-4594
To determine the feasibility of attaining acceptable rates of donor cell engraftment (>25% donor chimerism at 180 days) following reduced intensity conditioning (RIC) regimens in pediatric patients.
Duke University, Durham, NC.
- Jennifer H Baker, RN 919-668-6536, E Mail: baker133@mc.duke.edu
- Suhag Parikh, MD 919-668-1121, E Mail: suhag.parikh@duke.edu
This phase II trial is studying how well giving treosulfan together with fludarabine phosphate followed by donor stem cell transplant works in treating patients with noncancerous inherited disorders.
- Lauri Burroughs, MD 800-804-8824 or Clinical Trials Office - Seattle Cancer Care 800-804-8824